Glaukos is transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Glaukos Corporate Overview
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma.In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for
glaucoma, corneal health, and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in 9 regions around the world.
Empowering Ophthalmic Growth Worldwide
We’ll Go First
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. Our dedicated commitment to continuous innovation has resulted in an unrivaled pipeline of novel therapies.
We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.
Careers at Glaukos
Help put the next wave of disruptive technologies on the market.
Work with a team that’s dedicated to making a difference in the lives of patients worldwide.